Uracil

Uracil

SCHEMBL11130705

N.O=c1cc[nH]c(=O)[nH]1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Uracil SCHEMBL11607890 0.97
Uracil SCHEMBL5089507 0.97
Uracil SCHEMBL3798527 0.97 CRBN (1.00)
Uracil SCHEMBL8235 0.97
Uracil SCHEMBL18010636 0.94
Uracil SCHEMBL2557975 0.94
Uracil SCHEMBL228901 0.94
Uracil SCHEMBL3165194 0.94
Uracil SCHEMBL21385227 0.94
Uracil SCHEMBL710130 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117658936-A Synthesis method of 3,5, 6-trichloro- [1,2,4] -thiazine 上海予君生物科技发展有限公司 2024-03-08 CN claimed
CN-121951537-A Low-angle aluminum etching liquid composition 润晶(合肥)光电材料有限公司 2026-05-01 CN disclosed
US-20260085051-A1 PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID ADAMA AGAN LTD. (IL) 2026-03-26 US disclosed
CN-121045095-A Synthesis method of 6- (difluoromethyl) -2 hydrogen-1, 2, 4-triazabenzene-3, 5-dione 都创(上海)医药开发有限公司 2025-12-02 CN disclosed
EP-4313954-B1 PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID ADAMA AGAN LTD (IL) 2025-10-15 EP disclosed
CN-110787285-B XBP1, CD138 and CS1 peptides, pharmaceutical compositions comprising the peptides, and methods of using the peptides and compositions 达纳-法伯癌症研究所股份有限公司 2025-06-13 CN disclosed
CN-119192383-A ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies 诺华股份有限公司 2024-12-27 CN disclosed
CN-118994397-A Trispecific binding molecules directed against BCMA and uses thereof 诺华股份有限公司 2024-11-22 CN disclosed
CN-118974097-A Anti-PSMA antibodies, variants thereof, and uses thereof 西安奥瑞单抗生物技术有限公司 2024-11-15 CN disclosed
CN-110799640-B T cells expressing chimeric antigen receptors 综合医院公司 2024-11-12 CN disclosed
WO-2015090230-A1 HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF NOVARTIS AG (CH) 2015-06-25 WO disclosed
CN-104203985-A Cyclodextrin-based polymers for therapeutic delivery CERULEAN PHARMA INC 2014-12-10 CN disclosed
WO-2014078374-A2 METHODS FOR MULTIPLEXED DRUG EVALUATION PRESAGE BIOSCIENCES, INC. (US) 2014-05-22 WO disclosed
WO-2014071402-A1 XBP1, CD138, AND CS1, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PETIDES AND COMPOSITIONS DANA-FARBER CANCER INSTITUTE, INC. (US) 2014-05-08 WO disclosed
US-20140099263-A1 POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE CERULEAN PHARMA INC. (US) 2014-04-10 US disclosed
CN-103037903-A Compositions and methods for treating autoimmune or other diseases CERULEAN PHARMA INC 2013-04-10 CN disclosed
CN-102666533-A TREATMENT OF CANCER CERULEAN PHARMA INC 2012-09-12 CN disclosed
CN-102378626-A Polymer-agent conjugates, particles, compositions, and related methods of use CERULEAN PHARMA INC 2012-03-14 CN disclosed
US-20110028496-A1 Deuterium-enriched pyrimidine compounds and derivatives DHANOA DALJIT SINGH 2011-02-03 US disclosed
US-4474762-A Antibiotic compounds, their production and their medicinal use BAYER AKTIENGESELLSCHAFT (DE) 1984-10-02 US disclosed